Literature DB >> 170203

Candidate cytomegalovirus strain for human vaccination.

S A Plotkin, T Furukawa, N Zygraich, C Huygelen.   

Abstract

A strain of human cytomegalovirus called Towne was isolated in WI-38 human fibrolast cell cultures from the urine of an infected infant. It was then passaged 125 times in WI-38, including three clonings, and a pool was prepared in the same cell substrate for use as a potential live attenuated vaccine. The Towne virus has a broad antigenicity and cross-reacts with the AD-169 strain. Several markers of the Towne virus were found which differentiated it from fresh isolates. One of these was resistance of the former to trypsin. The Towne virus was tested for freedom from oncogenicity or other harmful effects in preparation for tests in humans.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 170203      PMCID： PMC415318          DOI： 10.1128/iai.12.3.521-527.1975

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  30 in total

1.  Immunisation trials with live attenuated cytomegalovirus TOWNE 125.

Authors:  M Just; A Buergin-Wolff; G Emoedi; R Hernandez
Journal:  Infection       Date:  1975       Impact factor: 3.553

2.  Latent cytomegalovirus infection in blood donors.

Authors:  P Diosi; E Moldovan; N Tomescu
Journal:  Br Med J       Date:  1969-12-13

3.  Antibody responses to the Epstein-Barr virus and cytomegaloviruses after open-heart and other surgery.

Authors:  W Henle; G Henle; M Scriba; C R Joyner; F S Harrison; R Von Essen; J Paloheimo; E Klemola
Journal:  N Engl J Med       Date:  1970-05-07       Impact factor: 91.245

4.  Asymptomatic cytomegalovirus infection following blood transfusion in tumor surgery.

Authors:  D P Stevens; L F Barker; A S Ketcham; H M Meyer
Journal:  JAMA       Date:  1970-02-23       Impact factor: 56.272

5.  Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero.

Authors:  S D Elek; H Stern
Journal:  Lancet       Date:  1974-01-05       Impact factor: 79.321

6.  Interactions of human cytomegalovirus with human fibroblasts.

Authors:  V Vonka; M Benyesh-Melnick
Journal:  J Bacteriol       Date:  1966-01       Impact factor: 3.490

7.  The attenuation, with loss of oncogenicity, of the herpes-type virus of Marek's disease (strain HPRS-16) on passage in cell culture.

Authors:  A E Churchill; R C Chubb; W Baxendale
Journal:  J Gen Virol       Date:  1969-06       Impact factor: 3.891

8.  Postperfusion syndrome. A review and report of 21 cases.

Authors:  T A Reyman
Journal:  Am Heart J       Date:  1966-07       Impact factor: 4.749

9.  Virulence and attenuation of murine cytomegalovirus.

Authors:  J E Osborn; D L Walker
Journal:  Infect Immun       Date:  1971-02       Impact factor: 3.441

10.  Post-transfusion cytomegaloviremia and persistence of cytomegalovirus in blood.

Authors:  D Armstrong; M Ely; L Steger
Journal:  Infect Immun       Date:  1971-01       Impact factor: 3.441
View more
  65 in total

1.  Human cytomegalovirus UL69 protein is required for efficient accumulation of infected cells in the G1 phase of the cell cycle.

Authors:  M L Hayashi; C Blankenship; T Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

2.  Coding potential of laboratory and clinical strains of human cytomegalovirus.

Authors:  Eain Murphy; Dong Yu; Jane Grimwood; Jeremy Schmutz; Mark Dickson; Michael A Jarvis; Gabriele Hahn; Jay A Nelson; Richard M Myers; Thomas E Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

3.  RASCAL is a new human cytomegalovirus-encoded protein that localizes to the nuclear lamina and in cytoplasmic vesicles at late times postinfection.

Authors:  Matthew S Miller; Wendy E Furlong; Leesa Pennell; Marc Geadah; Laura Hertel
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

4.  Stimulation of human lymphocytes by cytomegalovirions and dense bodies.

Authors:  I Sarov; A M Larsen; I Heron; H K Andersen
Journal:  Med Microbiol Immunol       Date:  1978-11-17       Impact factor: 3.402

5.  Cytomegalovirus infection of human arterial smooth muscle cell cultures can delay terminal passage.

Authors:  J J Tumilowicz
Journal:  In Vitro Cell Dev Biol       Date:  1991-11

6.  Onset of human cytomegalovirus replication in fibroblasts requires the presence of an intact vimentin cytoskeleton.

Authors:  Matthew S Miller; Laura Hertel
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

7.  Comparative activity of immunofluorescent antibody and complement-fixing antibody in cytomegalovirus infection.

Authors:  R F Betts; S D George; R B Rundell; R B Freeman; R G Douglas
Journal:  J Clin Microbiol       Date:  1976-08       Impact factor: 5.948

8.  [Experiments with simultaneous immunization against cytomegalovirus infection and rubella].

Authors:  M Just; A Bürgin-Wolff; R Hernandez
Journal:  Soz Praventivmed       Date:  1976 Sep-Oct

9.  A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in Cytomegalovirus-Seronegative Men.

Authors:  Stuart P Adler; Anne-Marie Manganello; Ronzo Lee; Michael A McVoy; Daniel E Nixon; Stanley Plotkin; Edward Mocarski; Josephine H Cox; Patricia E Fast; Pavlo A Nesterenko; Susan E Murray; Ann B Hill; George Kemble
Journal:  J Infect Dis       Date:  2016-08-11       Impact factor: 5.226

10.  Inactivation of human cytomegalovirus by sodium periodate oxidation.

Authors:  F Geoffroy; G Ogier; J Chantepie; G Quash
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.